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1.  Introduction  
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the 
‘Decision’) stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by 
a majority of its members, consider that the information provided by the Member 
State on a new psychoactive substance merits the collection of further information, 
this information shall be collated and presented by Europol and the EMCDDA in the 
form of a Joint Report (hereinafter the ‘Joint Report’).’ The Joint Report shall be 
submitted to the Council, the European Medicines Agency (EMA) and the European 
Commission. 
At the end of September 2013, the EMCDDA and Europol examined the available 
information on a new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-
methoxybenzyl)phenethylamine, commonly known by the abbreviation ‘25I-NBOMe’, 
through a joint assessment based upon the following criteria: 
1. the amount of the material seized; 
2. evidence of organised crime involvement; 
3. evidence of international trafficking; 
4. analogy with better-studied compounds; 
5. evidence of the potential for further (rapid) spread; and, 
6. evidence of cases of serious intoxication or fatalities. 
The EMCDDA and Europol agreed that the information collected on 25I-NBOMe 
satisfied criteria 1, 3, 5 and 6. The two organisations therefore concluded that 
sufficient information had been accumulated to merit the production of a Joint Report 
on 25I-NBOMe as stipulated by Article 5.1 of the Decision. 
2. Information collection process 
In compliance with the provisions of the Decision, on 7 October 2013 the EMCDDA 
and Europol launched a procedure for the collection of information on 25I-NBOMe, in 
order to prepare the Joint Report. The information was collected mainly through the 
Reitox National Focal Points in the Member States, Turkey and Norway as well as 
the Europol National Units. In addition, the EMA collected information through the 
national competent authorities responsible for human and veterinary medicinal 
products in the Member States as well as in Norway and Iceland. The information 
collection process was largely concluded by 18 November 2013; additional 
 
(1) OJ L 127, 20.5.2005, p. 32. 
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information and clarifications from some countries were received up to four weeks 
after this date. 
Europol asked the Europol National Units to provide information on: 
• the level of production of 25I-NBOMe in their country; 
• the level of distribution of 25I-NBOMe in their country; 
• the level of trafficking of 25I-NBOMe in their country, both for internal, transit 
or export purposes; 
• the number of seizures of 25I-NBOMe in their country, the total amount of the 
seizures, country of origin, details on the physical forms (including photos); 
• the role of organised crime, or criminal groups, in the production, distribution 
and trafficking of 25I-NBOMe in their country; and, 
• any known aspect of violence and/or money laundering relating to the 
production and trafficking of 25I-NBOMe. 
Europol received responses from 15 Member States. 
According to Article 5.3 of the Decision, the EMA requested the national competent 
authorities responsible for human and veterinary medicinal products in the Member 
States as well as in Norway and Iceland provide information on whether: 
• the new psychoactive substance 25I-NBOMe has obtained a marketing 
authorisation; 
• the new psychoactive substance 25I-NBOMe is the subject of an application 
for a marketing authorisation; and, 
• a marketing authorisation that had been granted in respect of the new 
psychoactive substance 25I-NBOMe has been suspended. 
Twenty-four Member States (2), Norway and Iceland responded to the EMA’s 
request. The EMA also provided information as relevant to the central authorisation 
procedure. 
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the 
manufacturing of medicinal products in the European Union, the EMA also requested 
whether the new psychoactive substance 25I-NBOMe is used to manufacture a 
medicinal product: 
• which has been granted a marketing authorisation; 
 
(2)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, 
Slovakia, Slovenia, Spain, Sweden, and the United Kingdom. 
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• for which an application has been made for a marketing authorisation; and, 
• for which a marketing authorisation has been suspended by a competent 
authority. 
Twenty-three Member States (3), Norway and Iceland replied to the EMA’s request. 
The EMA also provided information as relevant to the central authorisation 
procedure. 
The EMCDDA collected data through: 
1. a structured questionnaire from the Reitox National Focal Points. The EMCDDA 
received replies from 28 Member States as well as from Turkey and Norway; 
2. data previously provided to the EU Early Warning System via EMCDDA-Europol 
Reporting Forms, EWS Progress and Final Reports;  
3. a specific information request to the World Health Organization on whether or not 
methoxetamine is under assessment by the United Nations system (see section 
3.5), and; 
4. a structured search of the scientific literature and of relevant Internet sites. 
Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided 
by Europol, while the EMCDDA provided information included in sections 3.1, 3.2.2, 
3.4, 3.5, 3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information included in sections 
3.8.3 (in part), 4.1, 4.2 and 4.3 was provided by the EMA. The conclusion of the Joint 
Report was prepared and agreed by the two organisations responsible — the 
EMCDDA and Europol. Further details of the seizures and collected samples 
(including images where available) reported to the EMCDDA are provided in Annex 
1. The details of non-fatal intoxications and a death associated with 25I-NBOMe that 
have been reported to the EMCDDA are provided in Annex 2. 
3.  Information required by Article 5.2 of the Decision 
 
The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear 
in Article 5.2(a) to (h) and Article 5.3(a) to (c) of the Decision; all sections are cross-
referenced with those set down in the Decision. 
 
(3)  Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Germany, Greece, 
Hungary, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Poland, Portugal, Slovakia, 
Slovenia, Spain, Sweden, and the United Kingdom. 
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3.1 Chemical and physical description, including the names under which 
the new psychoactive substance is known — Article 5.2(a) of the 
Decision 
 
Chemical description and names 
 
25I-NBOMe is a derivative of 2C-I (4-iodo-2,5-dimethoxyphenethylamine), a known 
synthetic derivative of phenethylamine with stimulant and hallucinogenic properties. 
2C-I was the subject of a risk assessment at European level in 2003 (EMCDDA, 
2004). 25I-NBOMe contains the 2C-I substructure, substituted with a bulky ‘N-(2-
methoxy)benzyl’ group. The ‘I’ in 2C-I and 25I-NBOMe denotes the presence of an 
iodine atom in the structure (Figure 1). 
  
Several similar versions of 25I-NBOMe exist where the iodine atom is exchanged for 
another halide element, hydrogen atom or organic functional group, i.e. bromine 
(25B-NBOMe), chlorine (25C-NBOMe), hydrogen atom (25H-NBOMe), -methyl (25D-
NBOMe), -ethyl (25E-NBOMe), -nitro (25N-NBOMe) or –isopropyl (25iP-NBOMe). 
These compounds are informally called the ‘NBOMes’. This name comes from the 
‘N-benzylmethoxy’ substituent (-methoxy being written in chemical shorthand as 
‘OMe’). As of 12 December 2013, ten ‘-NBOMe’ compounds have been notified to 
the EU early warning system and it is important to note that –NBOMe compounds 
can be derived from all ‘2C’ phenethylamines. Furthermore, two simple variants of 
25I-NBOMe are possible by moving the methoxy group, found in position -2 on the 
benzyl moiety, to position -3 or -4. Furthermore, many other chemical variants are 
possible by changing the substitution pattern on the benzyl moiety to produce 
substances, the effects of which may or may not be similar to 25I-NBOMe.  
 
The IUPAC name for 25I-NBOMe is: 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine.  
 
Additional chemical synonyms have been reported: 
 
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine;  
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethan-1-amine; 
4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine; 
4-iodo-2,5-dimethoxy-N-(o-methoxybenzyl)phenethylamine; 
4-jodo-2,5-dimetoksi-N-(2-metoksibentsyyli)fenetyyliamiini (Finnish); 
4-iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine; 
N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine; and, 
N-(2-methoxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine. 
 
Furthermore, common names or codenames have also been reported: 25I, 2CI-
NBOMe or 2C-I-NBOMe, NBOMe-2C-I or NBOMe-2CI, BOM-CI, Cimbi-5, Solaris and 
INBMeO. 
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Finally, the following street names have been reported: ‘25I’, ‘dots’, ‘legal acid’, ‘N-
Bomb’, ‘NE-BOME’, ‘smiles’, ‘INBMeO’, ‘BOM-CI’, ‘Hoffman’ and ‘N-boom’. 
 
 
Figure 1. The numbered molecular structure, formula, weight and monoisotopic 
mass of 25I-NBOMe. The molecular structure for 2C-I is provided for comparison. 
 
 
 
25I-NBOMe  2C-I 
 
Molecular formula: C18H22INO3 
 
Molecular weight: 427.2767 
 
Monoisotopic mass: 427.064 
 
 
 
Chemical Abstract Service registry numbers (CAS RN) 
 
919797-19-6  free base 
1043868-97-8 hydrochloride salt 
1248338-50-2 11C radiolabelled base – 11C on the benzyl methoxy carbon 
1404305-56-1 11C radiolabelled base – 11C on the phenyl 2-methoxy carbon 
1043869-41-5 3H radiolabelled base 
 
The REACH registered substances database hosted by the European Chemicals 
Agency (ECHA) was searched using the CAS registry numbers listed above. The 
search returned no results. 
 
Physical description  
 
The hydrochloride salt form of 25I-NBOMe is a crystalline solid at room temperature. 
It has been reported that some Internet retailers (4) have advertised 25I-NBOMe as 
the free base and also as a hydroxypropyl-β-cyclodextrin (HPBCD) complex. In both 
 
(4) The term ‘Internet retailers’ is used in this report to describe Internet shops that offer new 
psychoactive substances for sale often advertised as ‘legal highs’ and ‘research chemicals’.  
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cases no reports have been received by the EMCDDA that have analytically 
confirmed the base/salt form or the presence of 25I-NBOMe in complex with HPBCD, 
although it is uncertain whether this would necessarily be detected with routine 
analytical techniques. 
 
Information provided from seizures and collected samples have noted the presence 
of 25I-NBOMe in blotters (small paper doses for sublingual/buccal administration), 
powders, powder-filled capsules and liquids. 
 
A more detailed description of 25I-NBOMe seizures and collected samples 
encountered can be found in subsections 3.2.1 and 3.2.2 below.  
3.2  Information on the frequency, circumstances and/or quantities in which 
a new psychoactive substance is encountered, and information on the 
means and methods of manufacture of the new psychoactive substance 
— Article 5.2(b) of the Decision 
3.2.1 Information provided to Europol 
Europol received replies from 15 Member States (Belgium, Bulgaria, Croatia, Cyprus, 
Estonia, Finland, Germany, Hungary, Italy, Latvia, Lithuania, Luxembourg, Poland, 
Slovakia and Slovenia). Of these, nine countries had no data relating to 25I-NBOMe 
(Bulgaria, Croatia, Cyprus, Estonia, Italy, Latvia, Lithuania, Luxembourg and 
Slovenia). The remaining six countries (Belgium, Finland, Germany, Hungary, Poland 
and Slovakia) reported the following information. 
The level of production, distribution and trafficking 
Belgium reported two seizures of 25I-NBOMe that were seized while in transit from 
China to the Netherlands. In the first case the substance was labelled as 
‘ETHYLENE VAE’ (107 g) and in the second case as ‘EGTAZIC ACID’ (51 grams). 
Finland reported that 71 seizures of 25I-NBOMe were made in the first half of 2013. 
In 68 cases, the substance was seized as blotters (10,004 units in total) and in three 
cases as liquid (20 ml in total).  
Germany reported that 11 seizures of 25I-NBOMe were made between November 
2012 and August 2013. The substance was seized in powder form in two cases, as a 
liquid in three cases and as blotters in six cases. In one seizure involving 10.7 grams 
of 25I-NBOMe powder that was made in April 2013, it was labelled as ‘1,2-Di(2-
aminoethoxy)-ethaneN,N,N,Ntetraacetic acid’. All three seizures of 25I-NBOMe in 
liquid form were made in June 2013 and ranged from 0.61 grams to 41.4 grams. In 
the majority of cases, the substance was seized in the form of blotters. 25I-NBOMe 
was also detected in mixtures with other substances, including: 25H-NBOMe, 25C-
NBOMe, JWH-122 N-(4-pentenyl) analogue, 2C-H-NBOMe and 2C-C-NBOMe. 
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Hungary reported ‘a few’ seizures of 25I-NBOMe in powder form and blotter form 
made since 2012. 
Poland reported that 25I-NBOMe had been seized on three occasions, with a total of 
48 blotters and ‘one piece of paper laced with substance’ seized. 
Slovakia reported one seizure of 25I-NBOMe in the form of a colourless liquid (1 ml). 
No reports were received that indicated licit or illicit production of 25I-NBOMe in any 
of these countries.  
3.2.2  Information provided to the EMCDDA 
 
Twenty-three Member States (Austria, Belgium, Czech Republic, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, 
Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and 
the United Kingdom) and Norway reported detections of 25I-NBOMe (5). 
Seizures  
Twenty-two Member States (Belgium, Czech Republic, Denmark, Estonia, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Netherlands, 
Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and the United 
Kingdom) and Norway reported seizures of 25I-NBOMe. 
25I-NBOMe has typically been seized as ‘blotters’ or paper ‘trips’. These are sheets 
of absorbent paper designed for sublingual or buccal administration. They are often 
printed with distinctive designs and perforated so they can be torn into small, single-
dose units (typically approximately 7 mm x 7 mm square). There are also reports of 
seizures in powder (including two seizures of capsules containing powder) and in 
liquid form (5% of cases). 
In most cases, 25I-NBOMe was reported as the only active substance, however, in 
about 10% of detections it was found in combination with other substances, including 
other ‘-NBOMe‘ compounds (25B-NBOMe, 25C-NBOMe, 25H-NBOMe, 25N-NBOMe, 
2C-C-NBOMe, 2C-I-NBOMe, 2C-H-NBOMe), 2C-B, 2C-C, 2C-I, 2C-T-4, mescaline 
(6), LSD, MDPBP (a synthetic cathinone) and an unknown substance. No quantitative 
analyses were available. 
 
(5) ‘Detections’ is an all-encompassing term and may include seizures and/or collected and/or 
biological samples. Seizure means a substance available (seized) through law enforcement 
activities (police, customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring and research 
purposes. Biological samples are those from human body fluids (urine, blood, etc.) and/or 
specimens (tissues, hair, etc.)  
(6) A naturally occurring hallucinogenic phenethylamine. 
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There is some evidence that 25I-NBOMe has been sold as a replacement for the 
internationally controlled hallucinogenic substance LSD (lysergic acid diethylamide) 
which is also commonly taken sublingually in the form of blotters. Seized 25I-NBOMe 
blotters varied in size (from 5 to 10 mm square), colour, and design (e.g. smiley, Felix 
the cat, Mickey Mouse, Rolling Stones tongue logo, Hoffman bicycle, etc.). Many of 
these designs have been associated with LSD in the past. Quantities of seized 
blotters ranged from one single unit (Denmark, Germany, Estonia, Finland, Poland, 
Slovakia and Norway) to 5154 units (Ireland); Finnish customs reported ten single 
seizures greater than 500 units. In a smaller number of cases, powders (from 0.025 
grams to 107 grams, Belgium), liquids (from 0.2 ml, Slovenia, to 75.2 grams, Poland) 
and capsules containing powder (10 units in Finland and 48 units in Norway) were 
seized.  
Finland reported more than half of the total number of seizures between June 2012 
and October 2013: 107 seizures from Helsinki airport postal customs and 14 seizures 
from the police. 25I-NBOMe was seized as blotters in most cases (111 seizures); the 
quantities seized ranged from a single blotter to 1200 units, with a total of 15796 
units. Small quantities were seized in other physical forms: powder (five seizures, 
ranging from 0.1 to 4.5 grams), liquid (four seizures, from 4 to 12 ml) and capsules 
containing powder (one seizure of 10 capsules). 
Denmark reported ten seizures of blotters (up to 263 units, from April to July 2013) 
and a seizure of powder (1.5 grams, January 2012).  
Germany reported ten seizures made in 2013. These included six seizures of 
blotters, three seizures of liquids (from 0.61 grams to 41.4 grams) and one powder 
(10.7 grams, labelled as ‘1,2Di(2-aminoethoxy)-ethaneN,N,N,Ntetraacetic acid’). 
In Poland, the first seizure of 25I-NBOMe (reported in 2011) was in liquid form; it has 
been mostly seized as blotters (up to 391 units) but also in powder form on two 
occasions (0.4 grams and 5.5 grams). 
Sweden detected 25I-NBOMe for the first time in May 2012 when 7 green blotters 
were seized. It reports a similar number of seizures of blotters and powders (5 to 583 
units and 1.49 grams to 13.82 grams, respectively).  
Norway reported nine seizures of blotters ranging from 1 to 250 units and one 
seizure of 48 capsules containing powder.  
France, Hungary, Italy and the United Kingdom reported more than five seizures. 
France reported mostly blotters (in some cases, blotters came in a plastic bag 
labeled '2 extra stamps’) but also one liquid and two powders; most of the seizures 
were made by customs authorities at Roissy airport (Paris). In Hungary, small 
quantities of blotters (from 2 to 17 units) and powders (10.66 grams and 12.73 
grams) were seized by the police. Italy (from 4 to 52 units) and the United Kingdom 
(from 3 to 2561 units) reported only seizing 25I-NBOMe in the form of blotters.  
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Belgium, Estonia, Greece, Ireland, Portugal and Spain reported less than five 
seizures. Belgian police seized ten blotters and customs authorities at Bierset airport 
(Liège) reported three seizures of powder, two of 75 grams and one of 107 grams 
which had arrived from China. Two seizures of blotters were reported by Estonia 
(one and 299 units) and Greece (2 and 103 units). Ireland reported the biggest single 
seizure of blotters, totalling 5154 units; Portugal reported four seizures of blotters 
(from 2 to 50 units) from June to September 2013; and Spain reported three 
detections of powder with no further details provided. 
Seven countries reported one seizure of 25I-NBOMe only: blotters in the Czech 
Republic (120 units), Latvia (124 units) and Romania (3 units); powder in Lithuania 
(0.025 grams) and the Netherlands (0.5 grams); and liquids in Slovakia (1 ml) and 
Slovenia (0.2 ml).  
Biological samples 
Three Member States (Belgium, Sweden and the United Kingdom) reported 
detections of 25I-NBOMe in biological samples. These included 15 non-fatal 
intoxications (Belgium, 3 cases; Sweden, 5; and the United Kingdom, 7) and one 
death in the United Kingdom. The United Kingdom also reported the detection of 25I-
NBOMe in three further cases: two criminal suspects in a drug-related death and an 
intoxicated driver. Further details are provided in section 3.4.1 and Annex 2. 
Collected samples  
Five Member States (Austria, Belgium, Italy, the Netherlands and Spain) reported the 
detection of 25I-NBOMe in collected samples. 
Austria reported six samples (all blotters), collected and analysed between February 
and October 2013 as part of the ‘pill’-testing project run by ‘ChEckiT!’. In five cases, 
the samples were sold as LSD and in the remaining case the sample was sold as 
mescaline. An unknown substance was also detected in one of the samples.  
Belgium reported a sample of five blotters collected in August 2013 as part of the 
investigations into one of the three non-fatal intoxications reported below. The 
blotters were collected from the patient and were found to contain 25I-NBOMe and 
traces of 25C-NBOMe.  
Italy reported a red blotter with a weight of 20 mg with a logo of a yellow/orange 
‘smile’ collected in the Veneto region. No other substances in addition to 25I-NBOMe 
were detected.  
The Netherlands reported 25I-NBOMe in six collected samples. Four cases involved 
blotters (amounting to a total of 16 blotters) and two involved samples of powder 
collected in 2012 and 2013. The samples were sold at consumer level either as 25I-
NBOMe (3 cases), LSD (2 cases) or 2C-E (1 case).  
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Spain reported three samples of blotters containing 25I-NBOMe which were collected 
at different venues in January 2013.  
Further details of these collected samples, including information on the product labels 
are provided in Annex 1. 
3.3 Information on the involvement of organised crime in the manufacture 
or trafficking of the new psychoactive substance — Article 5.2(c) of the 
Decision 
Germany reported that no links have been identified between organised crime groups 
and the production, trafficking and/or distribution of 25I-NBOMe. They also noted that 
it should be borne in mind that given the easy access to substances (which can be in 
large amounts) via Internet retailers it cannot be excluded that a certain level of 
organisation may exist. In addition, the interest and presence of organised crime 
groups in the phenomenon of new psychoactive substances can be easily concluded 
from the substantial profits that can be obtained from this type of activity. 
Money laundering aspects 
No information was received on money laundering connected to the production 
and/or trafficking of 25I-NBOMe. 
Violence in connection with production, wholesale and distribution 
No information was received on incidents of violence in connection with the 
production, wholesale and/or trafficking of 25I-NBOMe. 
3.4 A first indication of the risks associated with the new psychoactive 
substance, including the health and social risks, and of the 
characteristics of users — Article 5.2(d) of the Decision   
3.4.1 First indication of health risks 
A total of 32 non-fatal intoxications and three deaths associated with 25I-NBOMe 
were reported by four Member States: Belgium, Poland, Sweden and the United 
Kingdom. Not all of these cases have been analytically confirmed. See Annex 2 for 
further details on toxicologically confirmed cases. 
Non-fatal intoxications  
Belgium  
Belgium reported three non-fatal intoxications which occurred in August 2013. The 
cases were linked as the subjects had all been at the same party. All cases had 
analytical confirmation with 25I-NBOMe detected in urine and negative results for 
other drugs. 25I-NBOMe was not quantified but a pharmacokinetic study is being 
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performed on the collected blood samples. The patients were admitted to the 
hospital, having consumed ‘synthetic LSD’ and symptoms included lowered 
consciousness, insufficient breathing, mydriasis, tachycardia, hypertension and 
‘lessened strength in four extremities’ (see the details for all patients in Annex 2). The 
treatment was reported in two cases and included sedation, intubation and 
ventilation. The outcome is known for one patient whose symptoms disappeared 
after being under observation for a couple of hours. The patient reported having used 
25I-NBOMe in the past.  
Poland  
Poland reported four linked non-fatal intoxication cases which occurred in August 
2013. None of these cases were confirmed analytically. One of the patients reported 
they all had used 25I-NBOMe.  
Sweden 
Sweden reported 18 non-fatal intoxications which occurred between June 2012 and 
July 2013. Five of these cases have been analytically confirmed. Symptoms reported 
included mydriasis, anxiety, agitation, hallucinations, psychotic symptoms, 
tachycardia and hyperthermia. The routes of administration noted were oral, nasal 
and by injection. 
United Kingdom  
The United Kingdom reported seven non-fatal intoxications where 25I-NBOMe was 
detected and which occurred over the course of one week (Hill et al, 2013).  
The first case described by Hill et al. (2013) involved a 29-year old male who had 
purchased the drug from a ‘dealer’ in liquid form, labelled as ‘25I-NBOMe’. This 
person injected 3 ml of the liquid of unknown concentration intravenously. This case 
had the most severe symptoms reported by the United Kingdom including agitation, 
aggression, seizures, and self-harming behaviour associated with tachycardia, 
hypertension, tachypnea, oxygen desaturation, pyrexia and rhabdomyolysis. The 
patient also developed anuria with a subsequent acute kidney injury. A computed 
tomography (CT) scan revealed mild cerebral oedema but no other intracranial 
pathology. Treatment consisted of initial resuscitation with intubation, ventilation, 
intravenous sedation, antibiotics and fluids. Ongoing jerking seizure-like movements 
were noted and managed with atracurium infusion. Large doses of multi-modal 
sedation were administered during stabilisation. On day 18 of treatment a 
percutaneous tracheostomy was performed. The patient was discharged from 
intensive care on day 38, and discharged from hospital on day 43.  
In the other six cases, 25I-NBOMe had been taken at a house party after it had been 
purchased from the Internet. The 25I-NBOMe was in the form of powder contained in 
purple capsules, labelled as ‘2C-B’. The six cases were analytically confirmed either 
14 
in plasma alone or in urine and plasma. Amphetamine and methamphetamine were 
detected together with 25I-NBOMe in all six patients. 2C-I (7) was also detected in all 
available urine samples (4 of the 7 cases); this may suggest that 2C-I is a metabolite 
of 25I-NBOMe. In three cases the capsules were swallowed and in the other three 
cases, the powder from the capsule was nasally insufflated. The quantities 
consumed are inexact, but were reported to range from 1 capsule (3 cases) to ‘small 
amount’ or ‘~0.1 g’ of powder. The patients typically presented with agitation, 
aggressive behaviour, palpitations, visual and auditory hallucinations, mydriasis, 
pyrexia, but the symptomatology varied slightly between patients. One of these 
patients suffered severe toxicity, which required hospitalisation for 5 days (see the 
details of symptoms for all patients in Annex 2). He was treated with intravenous 
diazepam for agitation, was intubated and received pressure-controlled ventilation, 
anaesthesia with infusions of propofol, midazolam, and atracurium. The remaining 
five patients were discharged from hospital on the same day as admission or within 
15 hours and were treated with benzodiazepines (information available for three 
cases). Regular use of other illicit drugs was reported for three of the cases: one was 
a regular user of cocaine, cannabis and ecstasy and had previously used LSD; 
another had a history of regular amphetamine and ecstasy use; and, the third was a 
regular user of cannabis. One patient suffered from asthma and one patient was 
being treated with fluoxetine for depression. 
Deaths 
Belgium  
Belgium reported one death which occurred in October 2013. The cause of death has 
not been reported. The person died after consuming a blotter at a party that was 
believed to contain LSD; no LSD was detected in the toxicological analyses. Further 
details are not available at present. The results of the analytical confirmation on 
biological samples are awaited.  
Poland 
Poland reported a death which occurred in August 2013. The death was linked with 
the four non-fatal intoxications reported above. As noted, one of the four patients who 
received treatment reported they all had used 25I-NBOMe. The cause of death has 
not been reported and no analytical confirmation is expected. 
United Kingdom 
The United Kingdom reported a death by drowning which occurred in May 2013. 25I-
NBOMe was found on analysis of the post mortem blood of the deceased as well as 
 
(7)  2,5-Dimethoxy-4-iodophenethylamine  
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amphetamine, ketamine, lignocaine, 5-MeO-DiPT (8); DOI (9), 25C-NBOMe (10) and 
2C-I (7). No further information is available. 
Pharmacology and mode of action 
Data from in vitro studies has shown that 25I-NBOMe has nanomolar affinity for the 
serotonin 5-HT2A receptor and is a full agonist (Braden et al, 2006; Ettrup et al., 2010; 
Ettrup et al., 2011; Nichols et al., 2008). The addition of the 2-methoxybenzyl group 
significantly enhances the affinity and potency of 25I-NBOMe (Braden et al, 2006) 
compared to 2C-I (Blaazer et al., 2008).  
 
Stimulation of the 5-HT2A receptors appears to be essential for the hallucinogenic 
effects of drugs such as LSD (Egan et al. 1998, Marek & Aghaajanian, 1996; 
González-Maeso et al., 2007; Hanks & González-Maeso, 2013; Nelson et al., 1998). 
Given the fact that 25I-NBOMe is a potent full agonist for the 5-HT2A receptor and 
there have been reports of its hallucinogenic effects when used as a recreational 
drug, Halberstadt and Geyer (2013) studied the effect of 25I-NBOMe on the head-
twitch behavioural response (HTR) in mice which is used as a surrogate marker of 
the hallucinogenic effect of 5-HT2A receptor activation in humans (Hanks & González-
Maeso, 2013). The study found that 25I-NBOMe induces HTR in mice in a dose-
dependent manner, with a dose of 0.01 mg/kg s.c. inducing significant HTR 
compared to controls. HTR was dose-dependently antagonised by pre-treatment of 
the mice with the 5-HT2A receptor antagonist M100,907 suggesting that the HTR 
induced by 25I-NBOMe is mediated through 5-HT2A receptor activation. 
Toxicology 
No studies were identified that have examined the toxicity of 25I-NBOMe in vitro, in 
animals, or in humans. 
 
The clinical features of acute toxicity associated with 25I-NBOMe use as reported by 
the Member States are provided in section 3.4.1 ‘non-fatal intoxications’ and Annex 
2. These include a number of analytically confirmed cases (including those reported 
by Hill et al., 2013), and, in a subset, 25I-NBOMe was the only substance detected in 
the toxicology screen. Additional case reports/series from the United States were 
identified in the scientific literature (Kelly et al., 2012; Poklis et al., 2013; Rose et al., 
2012; Rose et al., 2013; Stellpflug et al., 2013). 
Dependence and abuse potential 
No studies were identified that have examined the dependence and abuse potential 
of 25I-NBOMe in vitro, in animals or in humans. 
 
(8) 5-Methoxy-di-isopropyl-tryptamine  
(9) 2,5-Dimethoxy-4-iodoamphetamine 
(10) 2-(4-Chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 
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Some self-reported experiences on user websites suggest re-dosing of 25I-NBOMe 
(e.g. Erowid, 2013a,b) although the available information does not allow for further 
comment. 
3.4.2 Characteristics of users 
No studies were identified that examined the characteristics of users of 25I-NBOMe. 
The section below includes a discussion of the characteristics of users which 
includes information from self-reported use from Internet drug discussion forums and 
related websites (hereafter ‘user websites’). As such it is important to note that it is 
not possible to confirm the specific substance(s) used, nor the purity, dose, etc. 
Analysis of products containing new psychoactive substances that are sold on the 
drug market have shown that the composition can differ between that claimed by the 
retailer, as well as differ over different geographical areas and time. Similar caveats 
apply to these types of information that have been provided in case reports/series 
unless biological and collected samples were taken and subjected to toxicological 
and forensic analysis. In addition, the information provided by patients in case 
reports/series as well as that provided on user websites should be regarded as 
illustrative only and not taken as representative of users of 25I-NBOMe in general. 
Finally, information from seizures, collected samples and user websites suggest that 
25I-NBOMe has been commonly sold as a ‘legal’ replacement for LSD (11) or sold as 
LSD directly on the illicit drug market. In the latter case users may be unaware that 
they are using 25I-NBOMe. Additional research is required in order to examine to 
what extent the characteristics of 25I-NBOMe users overlap and/or reflect those who 
use LSD. 
Route of administration, dose and drug regimens 
Information provided by the Member States, as well as from case reports/series and 
user websites suggests the routes of administration for 25I-NBOMe include 
sublingual, buccal, nasal (insufflation and absorption of liquid solutions), oral, 
injection (intravenous and intramuscular), rectal and smoking. 
Information from case reports/series and user websites suggest a range of doses are 
used that may depend on the route of administration. Example doses reported on the 
Erowid user website include: ‘750 ug, sublingual’; ‘3750 ug, sublingual’; ‘1000 ug, 
sublingual’; ‘1mg, buccal’; ‘1 blotter hit, sublingual/buccal’; ‘1000 ug, insufflated’; 
‘500-1000 ug, smoked’ (Erowid, 2013a). Further examples are provided in the 
section on ‘non-fatal intoxications’ (above) (see also: Drug Enforcement 
Administration, 2013a,b,c; Erowid, 2013a,b; Google, 2013a,b; Hill et al., 2013 (12); 
Stellpflug et al., 2013). 
 
(11)  For example use of the street names ‘legal acid’ and ‘Hoffman’. 
(12) In six of the seven cases reported by Hill et al. (2013), it is not clear if the patients intended to 
purchase and use 25I-NBOMe. The paper reports that ‘Cases 2–7 had used the 25I- NBOMe 
together at a house party after it had been purchased via the internet. The drug had arrived by 
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Information from user websites suggest that 25I-NBOMe may be used on its own as 
well as in combination with other new psychoactive substances and/or controlled 
drugs (Erowid, 2013b; Google 2013a; Google 2013b). In some of the non-fatal 
intoxications and deaths reported by the Member States as well as in case 
reports/series other new psychoactive substances and/or controlled drugs were 
detected in biological samples (Section 3.4.1 and Annex 2). 
Subjective effects 
No clinical trials were identified that have examined the subjective effects of 25I-
NBOMe in humans; information is largely limited to that provided in case 
reports/series (see ‘non-fatal intoxications’, above) and self-reported experiences 
from user websites. Table 1 provides an overview of duration of effects when 25I-
NBOMe is taken by the sublingual/buccal routes as well as when insufflated as 
reported by Erowid (2013a). Table 2 provides an overview of subjective effects of 
25I-NBOMe as reported by Erowid (2013a). In both cases the information was 
collated from users, research, and other resources. No further details were provided 
on the methodology used to collate this information. Information provided in case 
reports and case series of non-fatal intoxications associated with 25I-NBOMe appear 
to support some of these reports. 
Table 1. Examples of self-reported duration of effects of 25I-NBOMe per route of 
administration (tentative) as reported by Erowid (2013a). No information on the doses 
that were used was provided. 
Duration of effects for 25I-NBOME Sublingual / Buccal Insufflated 
Total duration 6–10 hrs 4–6 hrs 
Onset 15–120 mins 5–10 mins 
Coming up 30–120 mins 10–30 mins 
Plateau 120–240 mins 60–120 mins 
Coming down 60–240 mins 120–180 mins 
After effects 1–7 days 1–7 days 
Hangover / Day After ? ? 
 
                                                                                                                                       
mail as a powder enclosed in purple capsules and was labeled as ‘2C-B’’. The ‘2C-B’ 
presumably refers to 2-(4-bromo-2,5-dimethoxyphenyl)ethylamine; a ring-substituted 
phenethylamine which is subject to international control. 
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Table 2. Examples of subjective effects of 25I-NBOMe as reported by Erowid 
(2013a). No information on the doses that were used was provided. 
Subjective effects of 25I-NBOMe 
Positive Strong open and closed eye visuals, including trails, color shifts, brightening, etc. 
Mood lift 
Euphoria 
Mental and physical stimulation 
Increase in associative & creative thinking 
Increased awareness & appreciation of music 
Life-changing spiritual experiences 
Erotic, sexual thoughts and sensations 
Feelings of love and empathy 
Neutral General change in consciousness 
Pupil dilation 
Difficulty focusing 
Unusual body sensations (facial flushing, chills, goosebumps, body energy) 
Change in perception of time, time dilation 
Slight increase in heart rate 
Yawning, especially when coming up 
Does not suppress appetite 
Negative Confusion 
Looping  
Scrambled communication 
Nausea 
Insomnia 
Looping, recursive, out of control thinking 
Paranoia, fear, and panic 
Unwanted and overwhelming feelings 
Unwanted life-changing spiritual experiences 
Vasoconstriction, peripheral numbness, swelling of feet, hands, face 
Availability, supply, price 
A search of google.com using the search string ‘buy "25I-NBOMe"’ conducted by the 
EMCDDA in December 2013 for the Joint Report identified a number of online shops 
offering 25I-NBOMe for sale in both retail and wholesale quantities. In the former 
case 25I-NBOMe may be sold as a ‘research chemical’. 
Data from the National Drug and Alcohol Research Centre’s deep web monitoring 
programme of the Silk Road marketplace (13,14) (Van Buskirk et al., 2013) identified 
 
(13)  The National Drug and Alcohol Research Centre (NDARC) is based at the University of New 
South Wales, Sydney, Australia  
(14)  Silk Road is an anonymous, international online marketplace that operates as a Tor hidden 
service. It uses the peer-to-peer payment network and digital currency Bitcoin for monetary 
transactions. The original Silk Road marketplace was seized and taken offline on 2 October 
2013 by the United States Federal Bureau of Investigation. Since then a new version of Silk 
Road, sometimes described as ‘Silk Road 2.0’, has become operational. See Christin (2012) 
for an overview of the original Silk Road. 
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29 retailers in early February 2013 offering compounds from the ‘NBOMe family’ for 
sale. Details of the specific compounds offered, quantities, dosage forms, and prices 
were not provided. The number of such retailers was relatively stable over the 
preceding four months of monitoring (15). It is important to note that the study was 
conducted before Silk Road was seized and taken offline in October 2013 by the 
United States Federal Bureau of Investigation. No studies were identified that have 
examined the sale of ‘NBOMe’ compounds, including 25I-NBOMe, since Silk Road 
has reopened. 
Seizure data as well as information from collected samples reported by the Member 
States suggests that 25I-NBOMe is sold as a drug in its own right and directly on the 
illicit drug market as lysergic acid diethylamide (LSD). No information was reported 
on the price of 25I-NBOMe when sold as LSD. 
Prevalence of use 
Data from prevalence surveys 
No prevalence surveys were identified that have examined the use of 25I-NBOMe in 
the general population or in targeted populations.  
The recent report on the ‘NBOMe’ compounds by the Advisory Council on the Misuse 
of Drugs in the United Kingdom noted that “there was no evidence of significant use 
in recent self-report user surveys [it is unclear in the report if it refers to 25I-NBOMe 
or ‘NBOMe’ compounds] (Global Drug Survey, 2013), although there is evidence 
from club outreach services that ‘NBOMe’ is a popular club drug and that it is mostly 
bought from the Internet”. In addition the report also notes that the “prevalence of 
NBOMe compounds is very low in surveys with young adults conducted in nightclubs 
and festivals (personal correspondence with Professor Fiona Measham). They do not 
seem to be a drug of choice; they are not particularly prevalent and there is no 
evidence that they are associated with criminal behaviour, either through violent or 
acquisitive crime.” (Advisory Council on the Misuse of Drugs, 2013). 
Information from seizures and collected samples suggests that 25I-NBOMe is being 
sold directly on the illicit drug market as LSD. As such it may be relevant to consider 
the prevalence of LSD use. Among young adults (15- to 34-year-olds), lifetime 
prevalence of LSD use in Europe varies between countries, from 0.1 % to 5.4 % (16). 
Last year use of LSD in this age group ranges from 0 % to 1.7 % (17). Last 30 days 
 
(15)  29 retailers were identified in late October 2012; 33 in mid-November 2012; 27 in late 
November 2012; 29 in mid-December 2012; 24 in early January 2013; 24 in mid-January 2013. 
See Christin (2012) for a discussion of some of the market characteristics and dynamics of the 
original Silk Road. 
(16)  For further details, including the countries reporting data, see: 
http://www.emcdda.europa.eu/stats13#display:/stats13/gpstab1c  
(17)  For further details, including the countries reporting data, see: 
http://www.emcdda.europa.eu/stats13#display:/stats13/gpstab2b  
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prevalence of LSD use in this age group ranges from 0 % to 0.6 % (18). Lifetime 
prevalence of LSD (or other hallucinogen use, excluding hallucinogenic mushrooms) 
among 15- to 16-year-old school students ranged from 1 % to 5 % in 25 Member 
States and Norway with ESPAD (19) surveys in 2011, with only the Czech Republic 
reporting a prevalence level of 5 %. 
3.5 Information on whether or not the new substance is currently under 
assessment, or has been under assessment, by the UN system — 
Article 5.2(e) of the Decision 
The World Health Organization is the specialised United Nations agency designated 
for the evaluation of the medical, scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 1961 and the 
Convention on Psychotropic Substances, 1971. On 10 October 2013, the World 
Health Organization informed the EMCDDA that 25I-NBOMe is currently under 
assessment and ‘the critical review report will be published only early next year 
(probably April)’.  
Article 7.1 of Council Decision states that ‘no risk assessment shall be carried out in 
the absence of a Europol/EMCDDA Joint Report. Nor shall a risk assessment be 
carried out where the new psychoactive substance concerned is at an advanced 
stage of assessment within the United Nations system, namely once the WHO expert 
committee on drug dependence has published its critical review together with a 
written recommendation, except where there is significant new information that is 
relevant in the framework of this Decision’.  
The Joint Report has been produced on the understanding that 25I-NBOMe is not at 
an advanced stage of assessment within the United Nations system. 
3.6 The date of notification on the Reporting Form of the new psychoactive 
substance to the EMCDDA or to Europol — Article 5.2(f) of the Decision 
The first official EMCDDA–Europol notification of 25I-NBOMe dates from 21 June 
2012 from the Swedish national focal point. The Reporting form details a seizure of 
seven green blotters (paper doses) seized by police in Borlänge on 31 May 2012. 
The identification was based on the analytical technique of GC-MS (20) (library 
match). 
25I-NBOMe was added to the list of new psychoactive substances monitored by the 
EMCDDA and Europol through the European Union Early Warning System and a 
profile of the substance was created in the EMCDDA European Database on New 
Drugs (EDND). Since then analytical details, background information and public 
 
(18)  For further details, including the countries reporting data, see: 
http://www.emcdda.europa.eu/stats13#display:/stats13/gpstab3b  
(19) European school Survey Project on Alcohol and other Drugs. 
(20)  Gas chromatography-mass spectrometry. 
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health alerts have been exchanged between EMCDDA, Europol and the Member 
States on an ad hoc basis. The Commission and the EMA were kept duly informed. 
3.7 Information on whether or not the new psychoactive substance is 
already subject to control measures at national level in a Member State 
— Article 5.2(g) of the Decision 
Five Member States (Denmark, Latvia, Slovenia, Sweden, and the United Kingdom) 
as well as Norway reported that 25I-NBOMe is subject to control measures under 
drug control legislation. In Denmark it is controlled by the generic classification of 
phenethylamines in the Executive Order on Euphoriant Substances. In Latvia it is 
controlled according to Cabinet Regulation 847 “Regulations regarding narcotic 
substances, psychotropic substances and precursors to be controlled in Latvia”. In 
Slovenia it was included in a Decree amending the Decree on classification of illicit 
drugs, Official Gazette of RS No. 62/2013. In Sweden it is controlled under the 
Narcotic drugs control Act (SFS 1992-860) and the Narcotic drugs control Ordinance 
(SFS 1994:1554). In the United Kingdom it was placed under a temporary class drug 
order in June 2013. In Norway it is controlled by the generic scheduling of 
phenethylamines introduced on 14 February 2013. 
Four Member States (Austria, Hungary, Poland and Romania) reported that 25I-
NBOMe is subject to control measures under legislation covering unauthorised 
supply of defined or qualifying new psychoactive substances. In Austria it is 
controlled under the New Psychoactive Substances Act. In Hungary it falls within the 
generic definition of phenethylamines in Schedule C of Government Decree 66/2012. 
In Poland, 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act 
amending the Act on counteracting drug addiction and the Act on State Sanitary 
Inspection, 2010 and as such its marketing and production is penalized with a fine 
(administrative sanctions). In Romania it is controlled under Law 194 2011 which 
stipulates that all substances with psychoactive potential are subject to control until 
proven harmless by a special designated commission. 
Two Member States (Finland and the Netherlands) reported that 25I-NBOMe is 
subject to control measures under medicines legislation. In Finland it has been 
controlled since 15 March 2013 under the Medicines Act (395/87). In the 
Netherlands, when sold in consumer amounts it is treated as being a medicinal 
product and must comply with medicinal product legislation and general product 
safety legislation. 
Sixteen Member States (Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, 
Estonia, France, Germany, Greece, Ireland, Italy, Lithuania, Luxembourg, Malta, 
Portugal, and Slovakia) and Turkey have reported that 25I-NBOMe is not subject to 
control measures at the national level (21). 
No information was provided regarding the control status of 25I-NBOMe in Spain. 
 
(21) Germany and Turkey reported that they intend to introduce control measures for 25I-NBOMe. 
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3.8 Further information — Article 5.2(h) of the Decision 
3.8.1 The chemical precursors that are known to have been used for the 
manufacture of the substance 
 
No information was reported by the Member States, Turkey or Norway about the 
chemical precursors or manufacturing methods used to make 25I-NBOMe. Methods 
for the production of 25I-NBOMe are documented in the scientific literature. 
3.8.2 The mode and scope of the established or expected use of the new 
substance 
No studies were identified that have examined the mode and scope of established or 
expected use of 25I-NBOMe. Given the limited information currently available, much 
of the relevant information reported by the Member States as well as that from case 
reports/series published in the scientific literature and from user websites has been 
included in the previous sections. It is important to note in this respect that 
information from the Member States (such as seizures, collected samples, non-fatal 
intoxications) and user websites suggest that 25I-NBOMe may be commonly sold as 
a ‘legal’ replacement for LSD or sold as LSD directly on the illicit drug market. As a 
result, the mode and scope of use of 25I-NBOMe may, in part, overlap and/or reflect 
the mode and scope of use of LSD. Additional research is required in order to 
examine to what extent the mode and scope of 25I-NBOMe use overlap and/or 
reflect those of LSD. 
Settings of use 
Briefly, information from the Member States as well as from case reports/series 
suggests that 25I-NBOMe may be used in a range of settings, including the home 
environment (where an individual is on their own or in the company of others) and 
recreational settings. In the latter case this includes informal settings (such as ‘house 
parties’) as well organised events (such as ‘techno’ music events). 
The recent report on the ‘NBOMe’ compounds by the Advisory Council on the Misuse 
of Drugs in the United Kingdom noted that ‘evidence from club outreach services that 
‘NBOMe’ is a popular club drug and that it is mostly bought from the Internet’ 
(Advisory Council on the Misuse of Drugs, 2013). 
3.8.3 Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive 
substance, including the health and social risks 
 
No information was provided by the Member States, Turkey or Norway that indicated 
that 25I-NBOMe had any other use apart from legitimate scientific research and as 
an analytical reference standard.  
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Researchers have used radiolabelled (22) 25I-NBOMe as a tool to study the 
serotonergic system in the brain (Ettrup et al., 2010; Ettrup et al., 2011) as part of 
work that ultimately aims to further the understanding of the pathogenesis of human 
disease in which the serotonergic system may play a role. This includes research into 
its potential use as a tracer in Positron Emission Tomography imaging studies (Ettrup 
et al., 2010; Ettrup et al., 2011). Information on the management of health and safety 
hazards and risks that are associated with the use of such radiolabelled compounds 
were not provided by the Member States. However it is possible that these are 
addressed under relevant national regulatory systems governing the use of 
radioactive materials. 
 
From the available information it does not appear that 25I-NBOMe is used in the 
manufacture of a medicinal product in the European Union. However, the collection 
of information cannot be considered exhaustive in the absence of an European Union 
database on the synthetic routes of all medicinal products (23). 
4. Information from the EMA as requested by Article 5.3 of the Decision 
4.1 Marketing authorisation 
Twenty-four Member States, Iceland and Norway responded to the EMA’s 
information request (see section 2). They reported that the new psychoactive 
substance 25I-NBOMe has not obtained a marketing authorisation (24).The EMA also 
reported that the new psychoactive substance 25I-NBOMe has not obtained a 
marketing authorisation through the central authorisation procedure. 
4.2 Application for a marketing authorisation 
Twenty-four Member States, Iceland and Norway responded to the EMA’s 
information request (see section 2). They reported that the new psychoactive 
substance 25I-NBOMe is not the subject of an application for a marketing 
authorisation (24). The EMA also reported that the new psychoactive substance 25I-
 
(22) Information on radiolabelled new psychoactive substances may be held by competent 
authorities at the national level. Such authorities may be able to provide essential information 
on the uses of such compounds which may be important in assessing their use. 
(23) i.e. products that have been granted a marketing authorisation, or where an application for a 
marketing authorisation has been made, or where the marketing authorisation has been 
suspended. 
(24) Austria, Belgium, Croatia, Czech Republic, Denmark, Estonia, Germany, Greece, Hungary, 
Iceland, Ireland, the Netherlands, Norway, Portugal, Slovenia, Spain, Sweden and the United 
Kingdom provided responses in relation to both human and veterinary medicinal products. 
Cyprus, Italy, Lithuania, Malta and Slovakia provided responses in relation to human medicinal 
products. France, Latvia and Poland provided responses in relation to veterinary medicinal 
products. In addition the EMA provided information in relation to both human and veterinary 
medicinal products in respect to the central authorisation procedure. 
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NBOMe is not the subject of an application for a marketing authorisation through the 
central authorisation procedure. 
4.3 Suspended marketing authorisation 
Twenty-four Member States, Iceland and Norway responded to the EMA’s 
information request (see section 2). They reported that there had been no cases of a 
suspended marketing authorisation that had been granted in respect of the new 
psychoactive substance 25I-NBOMe (24). The EMA also reported that the new 
psychoactive substance 25I-NBOMe is not the subject of a suspended marketing 
authorisation through the central authorisation procedure. 
5. Conclusion 
25I-NBOMe is a substituted phenethylamine. It is a potent full agonist of the 
serotonin 5-HT2A receptor and appears to have hallucinogenic effects. It has been 
available on the European Union drug market since at least May 2012 and has been 
detected in 23 Member States and Norway. Severe toxicity associated with its use 
has been reported in four Member States and one death associated with 25I-NBOMe 
has been analytically confirmed. Seven countries have reported that it has been sold 
as LSD or as a ‘legal’ alternative to LSD. On this basis the potential impact from the 
further spread of 25I-NBOMe (and related ‘NBOMe’ compounds) on public health is a 
key concern. We conclude that the health and social risks caused by the 
manufacture, trafficking and use of 25I-NBOMe, as well as the involvement of 
organised crime and possible consequences of control measures, could be 
thoroughly assessed through a risk assessment procedure in accordance with Article 
6 of Council Decision 2005/387/JHA.
25 
References 
1. Advisory Council on the Misuse of Drugs, (2013), ‘‘NBOMe’ compounds: A review 
of the evidence of use and harm’, Home Office. 
https://www.gov.uk/government/publications/nbome-compounds-a-review-of-the-
evidence-of-use-and-harm 
2. Aghaajanian, G.K. and Marek, G.J. (1999), ‘Serotonin and hallucinogens’, 
Neuropyschopharmacology, 21 pp. 16S–23S. 
3. Blaazer, A.R., Smid, P., Kruse, C.G. (2008) ‘Structure-activity relationships of 
phenylalkylamines as agonist ligands for 5-HT(2A) receptors. ChemMedChem, 3 
pp. 1299–1309. 
4. Braden, M.R., Parrish, J.C., Naylor, J.C., Nichols, D.E. (2006) ‘Molecular 
interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) 
with superpotent N-benzyl phenethylamine agonists’, Molecular Pharmacology, 
70 pp. 1956–1964. 
5. Christin, N. (2012), Traveling the Silk Road: A measurement analysis of a large 
anonymous online marketplace. 
http://www.andrew.cmu.edu/user/nicolasc/publications/TR-CMU-CyLab-12-
018.pdf 
6. Drug Enforcement Administration (2013a), ‘Schedules of controlled substances: 
temporary placement of three synthetic phenethylamines into Schedule I’, 
Federal Register, 78 pp. 61991–3. 
7. Drug Enforcement Administration (2013b), ‘2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), 2-(4-
chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-
C-NBOMe; 25C; Cimbi-82) and 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-
methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36). 
Background information and evaluation of ‘Three Factor Analysis’ (Factors 4, 5 
and 6) for temporary scheduling. Drug Enforcement Administration. 
http://www.regulations.gov/contentStreamer?objectId=090000648147faf9&dispos
ition=attachment&contentType=pdf 
8. Drug Enforcement Administration (2013c), ‘Schedules of controlled substances: 
temporary placement of three synthetic phenethylamines into Schedule I. Final 
order’, Federal Register, 78 pp. 68716–9. 
9. Egan, C.T., Herrick-Davis, K., Miller, K., Glennon, R.A., Teitler, M. (1998), 
‘Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors’, 
Psychopharmacology, 136 pp. 409–414. 
10. EMCDDA, 2004. Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in 
the framework of the joint action on new synthetic drugs. EMCDDA, Lisbon, May 
2004. Available at: http://www.emcdda.europa.eu/html.cfm/index33353EN.html 
11. Erowid (2013a), 
http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_effects.shtml 
26 
12. Erowid (2013b), http://www.erowid.org/experiences/subs/exp_2CINBOMe.shtml  
13. Ettrup, A., Hansen, M., Santini, MA., Paine, J., Gillings, N., Palner, M., Lehel, S., 
Herth, M.M., Madsen, J., Kristensen, J., Begtrup, M., Knudsen, G.M. (2011), 
‘Radiosynthesis and in vivo evaluation of a series of substituted 11C-
phenethylamines as 5-HT (2A) agonist PET tracers’, European Journal of Nuclear 
Medicine and Molecular Imaging, 38 pp. 681–693. 
14. Ettrup, A., Palner, M., Gillings, N., Santini, M.A., Hansen, M., Kornum, B.R., 
Rasmussen, L.K., Någren, K., Madsen, J., Begtrup, M., Knudsen G.M. (2010), 
‘Radiosynthesis and evaluation of 11C-CIMBI-5 as a 5-HT2A receptor agonist 
radioligand for PET’, Journal of Nuclear Medicine, 51 pp. 1763–1770. 
15. González-Maeso, J., Weisstaub, N.V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, 
A., Bradley-Moore, M., Ge, Y., Zhou, Q., Sealfon, S.C., Gingrich, J.A. (2007), 
‘Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling 
pathways to affect behavior’, Neuron, 53 pp. 439–452. 
16. Google (2013a), https://www.google.com/search?q=site:bluelight.ru+25I-
NBOMe&ie=UTF-8&oe=UTF-8 
17. Google (2013b), https://www.google.com/search?q=site:drugs-forum.com+25I-
NBOMe&ie=UTF-8&oe=UTF-8 
18. Halberstadt, A.L., Geyer, M.A. (2013), ‘Effects of the hallucinogen 2,5-dimethoxy-
4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head 
twitch response’, Neuropharmacology, 77C pp. 200–207.  
19. Hanks, JB, González-Maeso, J. (2013), ‘Animal models of serotonergic 
psychedelics’, American Chemical Society Chemical Neuroscience, 16 pp. 33-42. 
20. Hill, S.L., Doris, T., Gurung, S., Katebe, S., Lomas, A., Dunn, M., Blain, P., 
Thomas, S.H. (2013), ‘Severe clinical toxicity associated with analytically 
confirmed recreational use of 25I-NBOMe: case series’, Clinical Toxicology, 51 
pp. 487–92. 
21. Kelly, A., Eisenga, B., Riley, B., Judge, B. (2012), ‘Case series of 25I-NBOMe 
exposures with laboratory confirmation’, Clinical Toxicology, 50 pp. 702. 
22. Marek GJ, Aghajanian GK. (1996), ‘LSD and the phenethylamine hallucinogen 
DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform 
cortex’, Journal of Pharmacology and Experimental Therapeutics, 278 pp. 1373–
1382. 
23. Nichols, D.E., Frescas, S.P., Chemel, B.R., Rehder, K.S., Zhong, D., Lewin, A.H. 
(2008). ‘High specific activity tritium-labeled N-(2- methoxybenzyl)-2,5-dimethoxy-
4-iodophenethylamine (INBMeO): A high-affinity 5- HT2A receptor-selective 
agonist radioligand’, Bioorganic & Medicinal Chemistry, 16 pp. 6116–6123. 
24. Poklis, J.L., Devers, K.G., Arbefeville, E.F., Pearson, J.M., Houston, E., Poklis, A. 
(2013) ‘Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-
[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high 
performance liquid chromatography with tandem mass spectrometry from a 
27 
traumatic death’, Forensic Science International. 
doi:10.1016/j.forsciint.2013.10.015 
25. Rose, R.S., Cumpston, K.L., Stromberg, P.E., Wills, B.K. (2012), ‘Severe 
poisoning following self-reported use of 25-I, a novel substituted amphetamine’, 
Clinical Toxicology, 50 pp. 707. 
26. Rose, S.R., Poklis, J.L., Poklis, A. (2013), ‘A case of 25I-NBOMe (25-I) 
intoxication: a new potent 5-HT2A agonist designer drug’, Clinical Toxicology, 51 
pp. 174–177. 
27. Stellpflug, S.J., Kealey, S.E., Hegarty, C.B., Janis, G.C. (2013), ‘2-(4-Iodo-2,5-
dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): 
Clinical case with unique confirmatory testing’, Journal of Medical Toxicology. 
doi:10.1007/s13181-013-0314-y 
28. Van Buskirk, J., Roxburgh, A., Bruno, R., Burns, L. (2013). Drugs and the 
Internet, Issue 1, August 2013. Sydney: National Drug and Alcohol Research 
Centre. 
http://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/DrugsTheInterne
t_Newsletter%20FINAL%20with%20ISSN.pdf 
 
28 
 
 
 
Annex 1 
 
 
EMCDDA–Europol Joint Report 
on a new psychoactive substance: 25I-NBOMe 
 
 
Images of 25I-NBOMe from seizures and collected samples 
 
 
Country Image Description 
 
Austria 
 
 
 
 
Collected sample, analysed in February 2013 
one blotter, sold as LSD (street name “DOC”) 
Contents: 25I-NBOMe and an unknown substance 
Collecting authority: ChEckiT! 
 
 
Austria 
 
 
 
Collected sample, analysed in February 2013 
one blotter, sold as LSD (street name “Hoffmann”) 
Collecting authority: ChEckiT! 
 
 
Austria 
 
 
 
 
Collected sample, analysed in March 2013 
three blotters, sold as LSD (4-10€). 
Contents: amphetamine (95 mg/g), caffeine (65 mg/g), 
Collecting authority: ChEckiT! 
 
 
Italy 
 
 
 
Seizure, January 2013 
8 blotters, seized in Bologna. 
Seizing authority: State Police of Bologna. 
 
Latvia 
 
 
 
 
Seizure, October 2013 
124 impregnated paper fragments, seized in 
Daugavpils. 
Seizing authority: Forensic service department by State 
police 
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Country Image Description 
 
Norway 
 
 
 
Seizure, March 2012 
250 squares of paper, seized in Stavanger. 
Seizing authority: Norwegian police 
 
Norway 
 
 
 
 
Seizure, February 2013 
1 piece of blotter paper, consisting of 59 squares with 
size: 1 x 1cm, seized in Ålesund. 
Seizing authority: Norwegian Customs 
 
Poland 
 
 
 
Seizures, May 2012 
5,4g of powder (package declared as containing 1-
Bromoindoline), seized in Kraków. 
Seizing authority: Customs Services Warsaw 
 
 
Poland 
 
 
 
 
 
Seizures, March and April 2013 
stamps, seized in Łódź, Kraków and Katowice. 
 
 
Romania 
 
 
 
Seizure, October 2013 
blotter paper, seized in Alba Iulia. 
Seizing authority: Romanian police 
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Country Image Description 
 
United 
Kingdom 
 
 
                
 
 
Seizure, May 2013 
19 apparent LSD tabs, seized in North East of 
Scotland. 
 
 
  
Annex 2 — Non-fatal and fatal intoxications associated with 25I-NBOMe  
Country Date of 
intoxication 
(gender, age) 
Biological 
sample 
25I-NBOMe 
result (1) 
Results for other 
substances (2) 
Notes 
Belgium August 2013 Urine + None reported Lowered consciousness, insufficient breathing, mydriasis, tachycardia (100/min) 
Belgium August 2013 Urine + None reported Lowered consciousness, insufficient breathing, mydriasis, tachycardia (100/min) 
Belgium August 2013 Urine + None reported Headache, lessened strength in 4 extremities, mydriasis, tachycardia (90/min), 
hypertension (150/85) 
Symptoms disappeared after being under observation for a couple of hours 
Sweden 2012 – 2013 Not 
reported 
+ None reported 25I-NBOMe detected in five non-fatal intoxications (no further details provided) 
United 
Kingdom 
 
January 2013 
(M, 29) 
Urine and 
plasma 
+ 2C-I, traces of 
amphetamine and 
methamphetamine 
Severe clinical toxicity. Agitation, aggression, seizures, self-harming behaviour, 
tachycardia (160/min), hypertension (187/171), tachypnea, oxygen desaturation, 
pyrexia, rhabdomyolysis. Respiratory and metabolic acidosis, elevation of 
creatine kinase, impaired renal function. Anuria with a subsequent acute kidney 
injury. Acute respiratory distress syndrome 
Discharged from intensive care unit on day 38, released from hospital on day 43 
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Country Date of 
intoxication 
(gender, age) 
Biological 
sample 
25I-NBOMe 
result (1) 
Results for other 
substances (2) 
Notes 
United 
Kingdom 
 
 
January 2013 
(M, 20) 
Urine and 
plasma 
+ 2C-I, traces of 
amphetamine and 
methamphetamine 
Severe clinical toxicity. Convulsions (predominantly affecting face), high agitation, 
poor respiratory effort and clenched jaw. Tachycardia, hypertension, tachypnea, 
urinary retention, pupillary dilatation, pyrexia, elevated creatine kinase. Visual 
hallucinations 
Released from hospital on day 5 
United 
Kingdom 
 
January 2013 
(M, 20) 
Urine and 
plasma 
+ 2C-I, traces of 
amphetamine and 
methamphetamine 
Palpitations, visual hallucinations. Pupillary dilatation, 3 inducible beats of ankle 
clonus, sinus tachycardia 
Discharged on the day of admission 
United 
Kingdom 
 
January 2013 
(M, 20) 
Urine and 
plasma 
+ 2C-I, traces of 
amphetamine and 
methamphetamine 
Palpitations, visual and auditory hallucinations. Tachycardia, pupillary dilatation 
Discharged on the day of admission 
United 
Kingdom 
 
January 2013 
(M, 19) 
Plasma + Traces of 
amphetamine and 
methamphetamine 
Euphoria with visual and auditory hallucinations, violent and agitated behaviour 
Discharged after 15 h 
United 
Kingdom 
 
January 2013 
(M, 22) 
Plasma + Traces of 
amphetamine and 
methamphetamine 
Nausea and visual hallucinations. Tonic-clonic seizure. Agitated and aggressive 
behaviour. Creatine kinase elevated 
Discharged on the day of admission 
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Country Date of 
intoxication 
(gender, age) 
Biological 
sample 
25I-NBOMe 
result (1) 
Results for other 
substances (2) 
Notes 
United 
Kingdom 
 
January 2013 
(M, 21) 
Plasma + Traces of 
amphetamine and 
methamphetamine 
Initial chaotic feeling followed by agitation, hallucinations and violent behaviour. 
Tachycardia and pyrexia 
Discharged after 15 h 
United 
Kingdom 
 
May 2013 
(M, 22) 
Blood 
(post-
mortem) 
+ Amphetamine, 
ketamine, 
lignocaine, 5-
MeO-DiPT, DOI, 
25C-NBOMe and 
2C-I 
Fatal intoxication 
Cause of death: drowning 
 
 
 
1 A ‘+’ in this column indicates 25I-NBOMe was detected but no quantification was provided. 
2 2C-I is 2,5-dimethoxy-4-iodophenethylamine 
5-MeO-DiPT is 5-methoxy-di-isopropyl-tryptamine 
DOI is 2,5-dimethoxy-4-iodoamphetamine 
25C-NBOMe is 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine 
 
 
 
 
